Ikris Health Plus- Online database of medicines available for export from India
18001200365 info@ikrishealthplus.com
Already a member? Register

Cookie Settings

Cookies are small text files stored on your device when you visit a website. They help websites function smoothly, improve performance, and provide insights into how users interact Learn more.

Unapproved Medicine Access from India

Access unapproved medicines from India with Ikris Health+, supporting global healthcare providers and distributors through regulated bulk supply solutions.

Access unapproved medicines from India through regulated pathways — Named Patient Supply (NPS), Compassionate Use, and Special Import Programs — with compliant sourcing, documentation support, and GDP-compliant cold-chain logistics.

Request a quote How access works

Pricing & availability support within 24 hours · info@ikrishealth.com

Hospitals & clinics Pharmaceutical importers & distributors Government healthcare bodies NGOs & humanitarian agencies Specialty pharmacies

When essential medicines aren't available locally, regulated pathways bridge the gap

Across the world, hospitals, healthcare providers, distributors, and pharmaceutical importers face situations where essential medicines are unavailable in their local market — due to delayed approvals, registration timelines, supply shortages, or limited commercial availability.

For patients facing critical illnesses, rare diseases, advanced cancers, autoimmune disorders, and life-threatening conditions, waiting is not always an option. This is where regulated global access pathways become essential.

At Ikris Health+, we support healthcare organizations with access to unapproved medicines from India through regulated procurement frameworks such as Named Patient Supply (NPS), Compassionate Use, and Special Import Programs. As a trusted unapproved medicine supplier from India, we work with hospitals, distributors, government bodies, importers, NGOs, and specialty procurement teams to support compliant international access to difficult-to-source medicines.

Our global sourcing solutions support access to

  • Oncology medicines
  • Biologics & biosimilars
  • Immunotherapy products
  • Rare disease medicines
  • Specialty hospital medicines
  • Autoimmune therapies
  • Hematology medicines
  • Neurology treatments
  • Critical care products

Supported by strong sourcing networks, GDP-compliant logistics, and international documentation support.

What are unapproved medicines?

Unapproved medicines are pharmaceutical products that may not yet hold commercial marketing authorization, full registration, or local approval in a specific country. These medicines may still be accessible through regulated healthcare frameworks where local laws permit controlled importation based on medical necessity.

In many countries, healthcare providers and authorized importers can access such medicines through regulated pathways when approved alternatives are unavailable or insufficient. As an experienced unapproved medicine exporter from India, Ikris Health+ supports organizations navigating these specialized procurement requirements.

Categories may include
  • Named patient medicines
  • Compassionate use of medicines
  • Early access therapies
  • Orphan drugs
  • Specialty biologics
  • Oncology immunotherapies
  • Investigational medicines
  • Limited-distribution medicines
  • Medicines facing local shortages

How access works

Each pathway exists for a specific clinical and regulatory situation. We support sourcing and export coordination across all three, aligned to country-specific requirements.

Named Patient Supply (NPS)

Regulated frameworks that allow physicians and healthcare institutions to procure medicines for individual patients with unmet medical needs.

Commonly used when:

  • No approved local treatment exists
  • Existing therapies are ineffective
  • Patients require urgent treatment continuity
  • The medicine is unavailable locally

Compassionate Use

Access to a medicine outside a clinical trial for patients with a serious or life-threatening condition, where no satisfactory authorized alternative is available.

Often sourced for:

  • Advanced oncology treatment
  • Rare disease management
  • Immunotherapy access
  • Specialty biologic therapies

Special Import Programs

Country-operated frameworks allowing controlled access to medicines not yet commercially registered within the country.

Commonly used when:

  • Medicines are under regulatory review
  • Local shortages affect supply continuity
  • Hospitals need specialty therapies
  • Emergency procurement is required

End-to-end coordination

Whichever pathway applies, we support sourcing, documentation, and compliant logistics — and we assist with country-specific procurement coordination for smoother import processes.

Talk to our procurement team

Challenges healthcare organizations face accessing unapproved medicines

Providers, hospitals, distributors, and procurement teams face multiple barriers when patients have urgent or specialized treatment needs. We help navigate each one.

Delayed regulatory approvals

Innovative therapies and specialty medicines can take significant time to receive local approval, limiting timely patient access.

Regional medicine shortages

Supply disruptions in local markets create critical gaps in treatment availability for hospitals and institutions.

Limited commercial distribution

Certain oncology medicines, biologics, orphan drugs, and specialty therapies have restricted channels or limited availability.

Access to orphan drugs

Rare disease treatments are difficult to source due to low commercial demand and specialized procurement requirements.

Import & compliance restrictions

International procurement involves complex import regulations, documentation, and country-specific approval pathways.

Cold-chain & logistics

Biologics and specialty medicines need temperature-controlled, GDP-compliant handling and secure international shipping.

One of the world's leading pharmaceutical sourcing hubs

India supports healthcare systems across regulated and semi-regulated markets globally. Buyers choose Indian suppliers for four core reasons.

Advanced manufacturing infrastructure

Internationally accredited facilities certified by WHO-GMP, US FDA, EU GMP, MHRA, PIC/S, TGA, ANVISA, and NAFDAC — enabling access to high-quality specialty medicines from trusted ecosystems.

Specialty & difficult-to-source access

Extensive access to oncology medicines, monoclonal antibodies, biosimilars, immunotherapy products, rare disease medicines, autoimmune therapies, specialty injectables, and hospital-use biologics.

Cost-efficient procurement

Scalable production capabilities and cost-efficient procurement models make India a practical choice for global healthcare buyers.

Strong export ecosystem

GDP-compliant logistics, cold-chain infrastructure, temperature-controlled shipping, global freight networks, and established export documentation systems.

Specialty medicine access across critical therapy areas

Oncology & immunotherapy

  • PD-1 inhibitors
  • Monoclonal antibodies
  • Targeted cancer therapies
  • Hematology-oncology products
  • Cancer biologics
  • Immuno-oncology medicines

Rare disease medicines

  • Orphan drugs
  • Metabolic disorder treatments
  • Enzyme replacement therapies
  • Specialized pediatric medicines

Autoimmune & immunology

  • Rheumatoid arthritis
  • Crohn's disease
  • Ulcerative colitis
  • Psoriasis
  • Ankylosing spondylitis

Hematology

  • Leukemia therapies
  • Lymphoma medicines
  • Multiple myeloma treatments
  • Blood disorder therapies

Neurology & specialty care

  • Multiple sclerosis
  • Neuromuscular disorders
  • Epilepsy
  • Advanced neurological treatments

Don't see your therapy area?

Our sourcing network spans a broad specialty portfolio. Share your requirement and we'll confirm availability.

Check availability

Regulated bulk supply of medicines from India

We support regulated bulk supply solutions for healthcare organizations and pharmaceutical procurement teams worldwide. As a trusted unapproved medicine exporter from India, we help organizations access regulated supply pathways for difficult-to-source medicines.

Our bulk procurement support includes:

  • Long-term procurement coordination
  • Institutional supply solutions
  • International sourcing support
  • Specialty medicine access
  • Export logistics coordination

Who we work with

  • Pharmaceutical importers
  • Global distributors
  • Hospitals & clinics
  • Hospital procurement departments
  • Government healthcare organizations
  • NGOs & humanitarian agencies
  • Specialty pharmacies
  • Institutional procurement teams

Regulatory & documentation support

International procurement requires strong documentation and regulatory coordination. We support:

  • Export documentation coordination
  • Regulatory support documentation
  • Product verification support
  • Batch traceability
  • International procurement assistance
  • Shipping documentation support

All documentation and certifications are available upon request, subject to product availability, manufacturer support, and importing-country requirements.

GDP-compliant logistics & cold chain

Reliable logistics are essential for specialty medicines and biologic therapies. Our support includes:

  • Global air freight shipping
  • GDP-compliant handling
  • Temperature-controlled transport
  • Cold-chain coordination & secure packaging
  • Shipment tracking & international freight coordination
  • 2–8°C cold storage
  • 15–25°C controlled transport
  • Frozen shipping (where applicable)

Global procurement across regulated and semi-regulated markets

We support country-specific import coordination and procurement requirements across four key regions.

LATAM

Procurement and unapproved medicine access across Latin American markets — Brazil, Argentina, Colombia, Peru, Chile, Ecuador, Bolivia, and Uruguay — with country-specific procurement coordination and import support.

Central America

Access under Named Patient Supply and Special Import Program frameworks, working with procurement partners in Costa Rica, Guatemala, Panama, Honduras, Nicaragua, Belize, and El Salvador.

Caribbean & North America

Regulated supply and specialty medicine procurement across the Dominican Republic, Puerto Rico, Haiti, and Cuba, with export and logistics coordination support.

Africa

Support for hospitals, distributors, NGOs, and institutions across Nigeria, Kenya, South Africa, Ghana, Ethiopia, Namibia, Senegal, Madagascar, and Chad — with compliant coordination, documentation, and logistics.

A responsible, compliant partner for specialty medicine access

NPS & Special Import expertise

We understand the complexity of global specialty medicine procurement and regulated access frameworks.

Strong sourcing network

A wide network of manufacturers, authorized suppliers, and specialty distribution partners across India.

Specialty medicine experience

Sourcing across oncology, biologics, rare disease therapies, immunology, hematology, and specialty hospital therapies.

Reliable export support

International shipping coordination, documentation support, procurement workflows, logistics, and regulatory coordination.

Responsible & compliant supply

All supply activities align with applicable regulations and procurement requirements in the importing country.

24h
Quote turnaround
8+
GMP accreditations

Important compliance notice

Unapproved medicines supplied from India are subject to local regulations, import permissions, healthcare authority approvals, and applicable pharmaceutical laws in the destination country.

Ikris Health+ supports access to unapproved medicines from India through regulated pathways such as Named Patient Supply, Compassionate Use, and Special Import Programs, where permitted by law.

We do not promote unauthorized medicine importation or bypass regulatory systems. Buyers, healthcare institutions, and importers are responsible for ensuring compliance with local regulations before procurement.

Request a quote for unapproved medicines from India

Looking to access unapproved medicines from India through regulated Named Patient Supply or Special Import Program pathways? We support hospitals, distributors, healthcare providers, and procurement organizations with compliant global sourcing and export coordination.

Email info@ikrishealth.com Submit an enquiry

Get pricing, availability, and procurement support within 24 hours.

Frequently asked questions

What are unapproved medicines?
Unapproved medicines are pharmaceutical products that may not yet hold local marketing authorization or commercial registration within a specific country.
Can unapproved medicines be imported legally?
Yes — many countries permit regulated importation of unapproved medicines through Named Patient Supply, Compassionate Use, or Special Import Program frameworks.
What is Named Patient Supply?
Named Patient Supply is a regulated pathway allowing physicians or healthcare institutions to procure medicines for individual patients with unmet medical needs.
What is a Special Import Program?
A Special Import Program allows authorized healthcare organizations or importers to access medicines not yet commercially available within the local market.
Can hospitals procure unapproved medicines from India?
Yes — hospitals and healthcare institutions may procure unapproved medicines from India, subject to local regulations and import permissions.
Does Ikris Health+ support bulk procurement?
Yes — we support institutional procurement, distributor supply, hospital procurement programs, and specialty pharmaceutical sourcing.
What therapeutic areas do you support?
We support oncology, biologics, immunology, hematology, rare disease medicines, autoimmune therapies, and specialty pharmaceuticals.
What countries do you export to?
We support exports to LATAM, Africa, Central America, Caribbean markets, and other international regions.
What documents are available?
We provide regulatory and export documentation support based on importing-country requirements and product availability.
How quickly can I receive a quotation?
Most inquiries receive pricing and availability support within 24 hours.

Regulatory references

WHO — GMP Standards U.S. FDA — Expanded Access / Compassionate Use EMA — Compassionate Use Programs Pharmexcil — Pharmaceuticals Export Promotion Council of India CDSCO, India — Central Drugs Standard Control Organization EMA — Human Medicines Overview WHO — Substandard and Falsified Medical Products ICH — Quality Guidelines

Ready to Get Started?

Contact us today to learn more about how we can help you access the medicines you need.

Contact Us Submit Enquiry